Kala Bio (KALA) Return on Equity [ROE] (2017 - 2026)
Kala Bio's Return on Equity [ROE] came in at -218.20% for Q2 2026, up 3320.41 percentage points from -3538.61% a year earlier and up 139.16 percentage points from the prior quarter.
Powered by 
Analysis
Kala Bio (KALA) Return on Equity [ROE] (2017 - 2026) Analysis & Trends
For FY2025, Kala Bio's Return on Equity [ROE] was -427.33%, up 23.47 percentage points from FY2024.
- Return on Equity [ROE] carries a five-year change of -266.44 percentage points (FY2020 to FY2025).
- Going back by year, Return on Equity [ROE] was -450.80% in FY2024 (-127.77 pp), -323.03% in FY2023 (+170.61 pp), -493.64% in FY2022 (-256.45 pp) and -237.20% in FY2021 (-76.31 pp).
- The Q2 2026 figure represents the highest quarterly Return on Equity [ROE] since Q3 2021.
- Year-over-year, Return on Equity [ROE] increased in three of the last six quarters, with an average year-over-year change of +53.36 percentage points.
- The fastest year-over-year change in Return on Equity [ROE] over five years came in Q2 2026 (a gain of 3320.41 percentage points), and the weakest in Q2 2025 (a drop of 3112.36 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | Kala Bio | 5.81 Mn | 5.81 Mn | - | -218.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -218.20% |
| Mar 31, 2026 | -357.36% |
| Jun 30, 2025 | -3,538.61% |
| Mar 31, 2025 | -478.10% |
| Dec 31, 2024 | -465.95% |
| Sep 30, 2024 | -435.59% |
| Jun 30, 2024 | -426.25% |
| Mar 31, 2024 | -609.47% |
| Dec 31, 2023 | -456.73% |
| Sep 30, 2023 | -304.81% |
| Jun 30, 2023 | -244.34% |
| Mar 31, 2023 | -319.78% |
| Dec 31, 2022 | -980.87% |
| Mar 31, 2022 | -2,448.78% |
| Dec 31, 2021 | -353.94% |
| Sep 30, 2021 | -165.71% |
| Jun 30, 2021 | -124.26% |
| Mar 31, 2021 | -107.52% |
| Dec 31, 2020 | -101.28% |
| Sep 30, 2020 | -81.01% |
API Access
Kala Bio Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=KALA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "KALA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=KALA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();